Personalised medicine (PM) is a cornerstone-field of healthcare, whose aim is to tailor the clinical diagnosis and treatment to the individual biochemistry of the patients and their particular molecular dysfunction.

This marks an essential shift from the paradigm of general treatment focussed on symptoms and should lead to:

significant improvements in clinical outcomes for patients
▶ increase in medical efficiency
▶ reduction of the financial burden of chronic health conditions on society

The importance of glycomics to healthcare
is summarised in a recent report endorsed by the US Academies which stated that “glycans are directly involved in the pathophysiology of every major disease” and that “additional knowledge from glycoscience will be needed to realize the goals of precision medicine and to take advantage of the substantial investments in human genome and proteome research and its impact on human health”.

GlySign focusses on glycomics for PM in clinical management of patients with long‐term chronic diseases, glycomics being defined here as determination of the structures and quantities of the glycan species in a particular biological system or glycoprotein, and so includes glycoproteomics. The name GlySign refers to the distinctive and complex changes in the glycomics profiles or Glycan Signatures of the body’s glycoproteins that occur during progression of many chronic diseases including cancers and inflammatory conditions